Recent Updates
Recently added Catalysts
ARVN Negative Sentiment Score: 25/100

ARVINAS ALERT: Bragar Eagel & Squire, P.C. is Investigating Arvinas, Inc. on Behalf of Arvinas Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Arvinas, Inc. on behalf of stockholders due to potential violations of federal securities laws. This follows Arvinas's recent decision to discontinue the development of vepdegestrant, an oral SERD for HR-positive breast cancer, resulting in a sharp decline in its share price. The sudden announcement, which included the halt of two planned Phase 3 studies, raised questions from analysts about the company's communication with investors. Stockholders affected by this situation are encouraged to reach out to the law firm for assistance.

Market Sentiment Analysis

CONCERNS & RISKS

  • Arvinas's discontinuation of vepdegestrant development led to a significant stock price drop.
  • The abrupt nature of the announcement left investors caught off guard.
  • Analysts expressed surprise and concerns about the transparency of Arvinas's management.

Full Press Release Details

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ:ARVN) on behalf of Arvinas stockholders. Our investigation concerns whether Arvinas has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On May 1, 2025, Arvinas and its partner Pfizer announced that they would discontinue development of vepdegestrant, an oral SERD for HR-positive breast cancer. The move eliminated two planned Phase 3 studies, following the termination of VERITAC-3 in January. According to The Fly, a financial news platform, Oppenheimer & Co. “was surprised by the announcement” and questioned whether “Arvinas’ management isn’t telling us the whole story.” Arvinas had repeatedly pointed to clinical progress for vepdegestrant and the drug’s commercial opportunity, leaving investors caught off guard by the abrupt pivot. On this news, the price of Arvinas shares declined by $2.39 per share, or approximately 25%, from $9.62 per share on April 30, 2025, to close at $7.23 on May 1, 2025.
If you purchased or otherwise acquired Arvinas shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the purpose of Bragar Eagel & Squire's investigation?

The firm is investigating potential claims against Arvinas for possible violations of federal securities laws.

Why did Arvinas' stock price decline recently?

Arvinas' stock fell by about 25% following the announcement to discontinue vepdegestrant's development.

What was announced on May 1, 2025, regarding Arvinas?

Arvinas and Pfizer announced they would stop developing vepdegestrant for breast cancer.

How can Arvinas stockholders get more information?

Stockholders can contact Brandon Walker or Marion Passmore via email or phone for details.

What does Bragar Eagel & Squire specialize in?

The firm specializes in representing investors in complex litigation related to securities.

Last updated: May 8, 2025